Comparative Pharmacology
Head-to-head clinical analysis: METICORTEN versus PREDNISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METICORTEN versus PREDNISONE.
METICORTEN vs PREDNISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisone is a prodrug that is converted to prednisolone, which binds to the glucocorticoid receptor, modulating gene expression and suppressing inflammation, immune response, and adrenal function.
Agonist at glucocorticoid receptors, leading to altered gene transcription that results in anti-inflammatory and immunosuppressive effects, including suppression of cytokines, prostaglandins, and leukotrienes.
5-60 mg orally once daily, depending on condition; for acute exacerbations, up to 250 mg IV every 4-6 hours.
5-60 mg orally once daily or divided twice daily; for acute indications, initial dose 5-60 mg/day; for chronic conditions, lowest effective dose; route: oral, intravenous, intramuscular.
None Documented
None Documented
Clinical Note
moderatePrednisone + Digoxin
"Prednisone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderatePrednisone + Digitoxin
"Prednisone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderatePrednisone + Deslanoside
"Prednisone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderatePrednisone + Acetyldigitoxin
"Prednisone may decrease the cardiotoxic activities of Acetyldigitoxin."
Following oral or IV administration, the terminal elimination half-life of total prednisolone (active form) is 2.1–3.5 hours in adults with normal hepatic function. In hepatic impairment, half-life may be prolonged (up to 6–8 hours), necessitating dose adjustment.
Terminal half-life: 2-3 hours (plasma); clinical effects persist for 12-36 hours due to intracellular actions and active metabolite prednisolone (half-life 3-4 hours).
Primarily renal: approximately 80% as inactive metabolites (conjugated and oxidized forms) and <5% as unchanged prednisolone. Biliary/fecal excretion accounts for about 10-15% of the dose.
Renal: <10% as unchanged drug; hepatic metabolism to inactive glucuronide and sulfate conjugates; fecal: ~20-30% via biliary elimination.
Category C
Category D/X
Corticosteroid
Corticosteroid